IM Cannabis reports C$1.65M revenue after European sale | Mugglehead

IM Cannabis revenue fell to C$1.65 million from C$5.08 million after the company sold its European operations on Sept. 29. Net loss widened to C$7.08 million. The company kept its Israeli medical cannabis business, reported a working-capital deficit of about C$5.50 million, and said a Polish drone acquisition remains non-binding.
Why it matters: For Israeli medical patients, the company's remaining business is the Israeli import, distribution and pharmacy operation, now with a thinner balance sheet. The shrinking revenue, working-capital deficit and reliance on convertible financing show how strained some cannabis operators remain, which can affect supply stability and a company's long-term staying power.
Reporting by mugglehead.com. Read the full story at mugglehead.com.
See how